4.83
-0.09(-1.83%)
Currency In USD
| Previous Close | 4.92 |
| Open | 4.88 |
| Day High | 4.88 |
| Day Low | 4.76 |
| 52-Week High | 12.4 |
| 52-Week Low | 3.21 |
| Volume | 9,859 |
| Average Volume | 670,576 |
| Market Cap | 297.09M |
| PE | 40.25 |
| EPS | 0.12 |
| Moving Average 50 Days | 4.42 |
| Moving Average 200 Days | 6.11 |
| Change | -0.09 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $228.05 as of June 13, 2025 at a share price of $4.83. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $701.02 as of June 13, 2025 at a share price of $4.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio Potency, selectivity, and long-lasting pha
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
GlobeNewswire Inc.
Apr 28, 2025 11:00 AM GMT
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4